Discussion
Proton-pump inhibitors are first-line drugs for the
treatment of gastric acid–related disorders and nonsteroidal
anti-inflammatory drug (NSAID)-induced
gastrointestinal lesions (1–3). Since the introduction
of omeprazole in 1989, other PPIs were approved,
namely, lansoprazole (1995), pantoprazole (1997),
rabeprazole (1999), esomeprazole (2001), and, more
recently, dexlansoprazole (2009).